GLPBio

Sumatriptan

Catalog No.: GC16634Purity:>98.00%
Sumatriptan (GR 43175 freie Base) ist ein oral aktiver 5-HT1-Rezeptoragonist mit einem Kis von 17 nM, 27 nM und 100 nM fÜr 5-HT1D-, 5-HT1B- bzw. 5-HT1A-Rezeptoren.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


Sumatriptan
Cas No.: 103628-46-2
10mM (in 1mL DMSO)In Stock
$20.00
1
10mgIn Stock
$18.00
1
25mgIn Stock
$32.00
1
50mgIn Stock
$45.00
1
100mgIn Stock
$68.00
1
200mgIn Stock
$95.00
1
500mgIn Stock
$162.00
1

Zitate (Citations)

Für dieses Produkt sind derzeit keine Zitate verfügbar. Nachfolgend finden Sie ausgewählte Publikationen, die GlpBio-Produkte zitieren.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Beschreibung (Description)

Sumatriptan is an orally active 5-HT1 receptor agonist with IC50 values of 7.3nM, 9.3nM and 17.8nM for 5-HT1D, 5-HT1B and 5-HT1F receptors, respectively[1]. 5-HT1 receptor is a G-protein-coupled receptor subfamily that inhibits adenylyl cyclase and modulates serotonin-mediated neurotransmission[2]. Sumatriptan is usually used for migraine headache research[3].

In vitro, Sumatriptan(10pM-10μM; 20min) displaced [³H]-5-HT with an IC50 of 5.0nM and fully stimulated [35S]-GTPγS binding with an EC50 of 16nM in CHO cells stably expressing human 5-HT1D receptors[4]. Sumatriptan(10pM-10μM; 20min) inhibited forskolin-stimulated cAMP accumulation in HEK-293 cells expressing h5-HT1B receptors (IC50=20nM) and in C6-glioma cells expressing h5-HT1D receptors (IC50=2.6nM)[5].

In vivo, Sumatriptan (600μg/kg; i.p.) reversed nitroglycerin (NTG)-induced thermal and mechanical allodynia in male C57BL/6 mice, and restored withdrawal latencies and thresholds to baseline within 60min[6]. Sumatriptan (0.3mg/kg/day; i.p.; 28 days) reversed T9-10 clip-compression–induced mechanical and thermal allodynia, reduced spinal TNF-α, IL-1β and CGRP, and improved BBB locomotor scores in adult male Sprague-Dawley rats[7].

References:
[1] Peroutka SJ, McCarthy BG. Sumatriptan (GR 43175) interacts selectively with 5-HT1B and 5-HT1D binding sites. Eur J Pharmacol. 1989;163(1):133-136.
[2] Polter AM, Li X. 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal. 2010;22(10):1406-1412.
[3] Dechant KL, Clissold SP. Sumatriptan. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs. 1992;43(5):776-798.
[4] Castro JL, Street LJ, Guiblin AR, et al. 3-[2-(Pyrrolidin-1-yl)ethyl]indoles and 3-[3-(piperidin-1-yl)propyl]indoles: agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B subtype. J Med Chem. 1997;40(22):3497-3500.
[5] Lesage AS, Wouters R, Van Gompel P, et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998;123(8):1655-1665.
[6] Bates EA, Nikai T, Brennan KC, et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 2010;30(2):170-178.
[7] Afshari K, Dehdashtian A, Haddad NS, et al. Sumatriptan improves the locomotor activity and neuropathic pain by modulating neuroinflammation in rat model of spinal cord injury. Neurol Res. 2021;43(1):29-39.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

HEK 293 cells

Preparation Method

HEK 293, a human transformed embryonic kidney cell line, was grown in Dulbecco's modi®ed Eagle's medium containing 1mM sodium pyruvate, 2mM L-glutamine, antibiotics and 10% foetal calf serum. The selection and culture medium for HEK 293 cells expressing the 5-HT 1B receptor contained an extra 800μg/ml geneticin. Geneticin was left out at least 2 days before assay. Cells were grown at 37℃ in humidi®ed air with 5% CO2. Cells were plated in Multi-well 24 plates. The next day, cells were washed and incubated for 20min in the presence of 10pM-10μM Sumatriptan with controlled salt solution (composition in mM : NaCl=120, KCl=5, MgCl2=0.8, CaCl2=1.8, glucose=15 and phenol red=0.04 in 25mM Tris-HCl, pH 7.4) containing either 100μM forskolin or solvent. The incubation was stopped with ice-cold HClO4. The extract was neutralized to pH 7.5 with K3PO4/KOH solution. After precipitation of KClO4 at 4℃, plates were centrifuged, and the supernatant was assayed for cyclic AMP content with a commercial [ 125 I]-cyclic AMP radioimmunoassay kit according to the procedure recommended by the manufacturer. The cyclic AMP levels were expressed as percentage of forskolin-stimulated cyclic AMP production (set at 100%), and plotted against the drug concentration on a logarithmic scale. Sigmoidal curves of best ®t were calculated by non linear regression analysis. The pIC50 value referred to the concentration of a compound producing half the maximum reduction in cyclic AMP seen with 5-HT.

Reaction Conditions

10pM-10μM; 20min

Applications

Sumatriptan inhibited forskolin-stimulated cAMP accumulation in HEK-293 cells expressing h5-HT1B receptors (IC50=20nM).

Animal experiment [2]:

Animal models

C57BL6 male mice

Preparation Method

All experiments were conducted on C57BL6 male mice weighing 20-30g. Animals were housed in a 12-h light–dark cycle. Experiments were conducted between 09.00 and 14.00h at a temperature of 22°C. A stock of 5.0mg/ml NTG dissolved in 30% alcohol, 30% propylene glycol, and water was freshly diluted each day in 0.9% saline in a polypropylene tube. Doses of 0.5, 1, 5 or 10mg/kg were administered intraperitoneally. Control mice received an intraperitoneal injection of 0.9% saline. Five minutes after the administration of 10mg/kg NTG, each animal was treated with i.p. Sumatriptan(600μg/kg) or saline. Alternatively, an identical set of NTG-injected mice was treated with a single injection of intrathecal Sumatriptan (0.06μg in 5μl) or saline at 5min after NTG administration. Animals were habituated to the testing apparatus for 60min on the day prior to and again immediately before determination of baseline nociceptive thresholds. Each group of animals underwent one of two different tests before and following NTG injection. Hargreaves assay was used to determine thermal nociceptive thresholds. Mechanical nociceptive thresholds were determined with von Frey monofilaments.

Dosage form

600μg/kg; i.p.

Applications

Sumatriptan reversed nitroglycerin (NTG)-induced thermal and mechanical allodynia in male C57BL/6 mice.

References:
[1] Lesage AS, Wouters R, Van Gompel P, et al. Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT1B and 5-HT1D receptors expressed in various mammalian cell lines. Br J Pharmacol. 1998;123(8):1655-1665.
[2] Bates EA, Nikai T, Brennan KC, et al. Sumatriptan alleviates nitroglycerin-induced mechanical and thermal allodynia in mice. Cephalalgia. 2010;30(2):170-178.

Produktdokumente (Product Documents)

Purity:>98.00%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
103628-46-2
Chemischer Name
1-(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)-N-methylmethanesulfonamide
SMILES
CNS(CC1=CC(C(CCN(C)C)=CN2)=C2C=C1)(=O)=O
Summenformel
C14H21N3O2S
Molekulargewicht
295.4
Löslichkeit
≥ 14.77mg/mL in DMSO
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for Sumatriptan

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%